Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 423-429

  Jones, Robin L ^a,b   Olmos, David ^a,b   Thway, Khin ^a   Fisher, Cyril ^a   Tunariu, Nina ^b   Postel Vinay, Sophie ^a,b   Scurr, Michelle ^a,b   De Bono, Johann ^b   Kaye, Stan B ^b   Judson, Ian R ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Overall survival; Phase I; Progression free survival; Response; Sarcoma; Toxicity

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; ANGIOGENESIS INHIBITOR;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CHONDROSARCOMA; FEMALE; FIBROSARCOMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SARCOMA; SCHOOL CHILD; SOLITARY FIBROUS TUMOR; SYNOVIAL SARCOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, PUBLIC; HUMANS; LONDON; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT DROPOUTS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79960921969     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1484-9     Document Type: Article

References (19)

1. JS Wunder TO Nielsen RG Maki B O'Sullivan BA Alman 2007 Opportunities for improving the therapeutic ratio for patients with sarcoma Lancet Oncol 8 6 513 524 17540303 10.1016/S1470-2045(07)70169-9 (Pubitemid 46823060)
2. MA Clark C Fisher I Judson JM Thomas 2005 Soft-tissue sarcomas in adults N Engl J Med 353 7 701 711 16107623 10.1056/NEJMra041866 1:CAS:528: DC%2BD2MXos1ClsLc%3D (Pubitemid 41175678)
3. D Krikelis I Judson 2010 Role of chemotherapy in the management of soft tissue sarcomas Expert Rev Anticancer Ther 10 2 249 260 20132000 10.1586/era.09.176 1:CAS:528:DC%2BC3cXhsFGit7k%3D
4. F Grosso RL Jones GD Demetri, et al. 2007 Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol 8 7 595 602 17586092 10.1016/S1470-2045(07)70175-4 1:CAS:528:DC%2BD2sXnsFKkur0%3D (Pubitemid 46995623)
5. KM Skubitz PA Haddad 2005 Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma Cancer 104 2 361 366 15948172 10.1002/cncr.21140 1:CAS:528:DC%2BD2MXnslymu7o%3D (Pubitemid 40993264)
6. J Verweij A van Oosterom JY Blay I Judson S Rodenhuis W van der Graaf J Radford A Le Cesne PC Hogendoorn ED di Paola M Brown OS Nielsen 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 14 2006 2011 12957454 10.1016/S0959-8049(02)00836-5 1:CAS:528:DC%2BD3sXmvVKgtrc%3D (Pubitemid 37297756)
7. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 1329 1338 17046465 10.1016/S0140-6736(06) 69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL (Pubitemid 44528723)
8. D Olmos DS Tan RL Jones IR Judson 2010 Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside Cancer J 16 3 183 194 20526094 10.1097/PPO.0b013e3181dbebf9 1:CAS:528: DC%2BC3cXovV2rt74%3D
9. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11(2):129-135
10. Albiges-Sauvin L, Gomez-Roca C, Domont J, Bahleda R, Gombos A, Armand JP, Pautier P, Le Cesne A, Soria JC, Massard C (2008) Is there a substantial clinical benefit for sarcoma patients included in phase I trials? European Society of Medical Oncology Conference, Stockholm
11. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98(6):1029-1033 (Pubitemid 351399798)
12. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27(16):2692-2696
13. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. JM Coindre P Terrier L Guillou V Le Doussal F Collin D Ranchère X Sastre MO Vilain F Bonichon B N'Guyen Bui 2001 Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group Cancer 91 10 1914 1926 11346874 10.1002/1097-0142(20010515)91: 10<1914::AID-CNCR1214>3.0.CO;2-3 1:STN:280:DC%2BD3M3ltVKmsA%3D%3D (Pubitemid 32424119)
15. H Hashimoto Y Daimaru S Takeshita M Tsuneyoshi M Enjoji 1992 Prognostic significance of histologic parameters of soft tissue sarcomas Cancer 70 12 2816 2822 1451060 10.1002/1097-0142(19921215)70:12<2816::AID-CNCR2820701215>3. 0.CO;2-4 1:STN:280:DyaK3s%2Fot1KitA%3D%3D
16. V Karavasilis BM Seddon S Ashley O Al-Muderis C Fisher I Judson 2008 Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer 112 7 1585 1591 18278813 10.1002/cncr.23332 (Pubitemid 351441172)
17. Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR (2010) Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Epublished in Sarcoma
18. M Van Glabbeke J Verweij I Judson OS Nielsen OS Nielsen EORTC Soft Tissue and Bone Sarcoma Group 2002 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 4 543 549 11872347 10.1016/S0959-8049(01)00398-7 (Pubitemid 34185394)
19. Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR (2010) Chemotherapy in clear cell sarcoma. Epublished in Med Oncol